Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of March 8 to 12, 2021. This […]
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of March 8 to 12, 2021. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
Over Half Have Symptoms of Major Depressive Disorder After COVID-19
FRIDAY, March 12, 2021 (HealthDay News) — More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder, according to a research letter published online March 12 in JAMA Network Open.
Novavax COVID-19 Vaccine Highly Effective in Clinical Trials
FRIDAY, March 12, 2021 (HealthDay News) — A COVID-19 vaccine developed by Novavax was 96 percent effective against the original strain of the coronavirus in preventing mild, moderate, and severe cases of illness and was 100 percent effective against severe disease caused by new, more contagious variants, two new clinical trials show.
Pfizer COVID-19 Vaccine 97 Percent Effective Against Symptomatic Disease
FRIDAY, March 12, 2021 (HealthDay News) — The Pfizer COVID-19 vaccine is 97 percent effective in preventing symptomatic disease in actual use, which is better than previously thought.
In Under 25s, Racial, Ethnic Disparities in COVID-19 Incidence Varied
FRIDAY, March 12, 2021 (HealthDay News) — Among persons younger than 25 years old, racial and ethnic differences in COVID-19 incidence varied through 2020, according to research published in the March 10 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Immune Response Strong After One Dose in COVID-19-Seropositive Vaccinees
FRIDAY, March 12, 2021 (HealthDay News) — Individuals with preexisting immunity receiving an mRNA vaccine for COVID-19 have higher antibody titers after one dose than those without preexisting immunity, according to a letter to the editor published online March 10 in the New England Journal of Medicine.
One Year Into Pandemic, Biden Promises Vaccines for All U.S. Adults by May 1
FRIDAY, March 12, 2021 (HealthDay News) — During a speech reassuring Americans that the pandemic could be nearing its end in this country, President Joe Biden on Thursday promised that all U.S. adults will be eligible for a COVID-19 vaccine by May 1.
Guidelines Provided for Unilateral Lymphadenopathy After COVID-19 Vaccination
FRIDAY, March 12, 2021 (HealthDay News) — In a report published online March 4 in the Journal of the American College of Radiology, guidelines are provided for the management of unilateral axillary lymphadenopathy identified on imaging tests in the context of COVID-19 vaccination.
Biden Announces Plan to Buy 100 Million More Doses of J&J Vaccine
Significant Association ID"d Between Hepatitis C, Overactive Bladder .jpg)
Study Looks at Barriers to Initiation of Rotavirus Vaccine 
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2 
Obstructive Sleep Apnea Tied to Nearly Doubled Risk for Flu, COVID-19 in Childhood 
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children 
Physical Exams May Not Reliably Diagnose Pediatric Pneumonia .jpeg)
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay 
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older 
